Multimeric il-15 soluble fusion molecules and methods of making and using same
US-2020181237-A1 · Jun 11, 2020 · US
Multimeric IL-15 soluble fusion molecules and methods of making and using same
US11046747B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11046747-B2 |
| Application number | US-202016749955-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 22, 2020 |
| Priority date | Sep 21, 2010 |
| Publication date | Jun 29, 2021 |
| Grant date | Jun 29, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
First claim
Opening claim text (preview).
What is claimed is: 1. A kit comprising: an effective amount of an interleukin-15N72D:IL-15 receptor alpha Sushi/Fc (IL-15N72D:IL-15RαSu/Fc) complex, wherein the complex comprises a dimeric IL-15RαSu/Fc and two IL-15N72D molecules (ALT-803); and directions for use of the kit. 2. The kit of claim 1 wherein the IL-15RαSu/Fc comprises SEQ ID NO.: 1. 3. The kit of claim 1 , wherein a IL-15N72D molecule comprises SEQ ID NO.: 2. 4. The kit of claim 1 , wherein the effective amount is between about 1 and 20 μg/kg. 5. The kit of claim 1 , wherein the effective amount is about 1 μg/kg. 6. The kit of claim 1 , wherein the effective amount is about 5 μg/kg. 7. The kit of claim 1 , wherein the effective amount is about 10 μg/kg. 8. The kit of claim 1 , wherein the effective amount is about 20 μg/kg. 9. The kit of claim 1 , wherein the effective amount is between about 20 μg and 100 μg/kg. 10. The kit of claim 1 , wherein the effective amount is about 30 μg/kg. 11. The kit of claim 1 , wherein the effective amount is about 50 μg/kg. 12. The kit of claim 1 , wherein the effective amount is about 75 μg/kg. 13. The kit of claim 1 , wherein the effective amount is about 100 μg/kg.
Assignees
Inventors
Classifications
for HIV · CPC title
Antivirals · CPC title
Recombinant DNA-technology · CPC title
against CD20 · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11046747B2 cover?
- The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).
- Who is the assignee on this patent?
- Altor Bioscience Llc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/7155. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).